

Reference list

CliniMACS[®] System – NK cells

Contents

1. **Clinical study results – Patient treatment with NK cell products**
2. **Technical performance and NK cell functionality data and pre-clinical data**
3. **Reviews**

1. Clinical study results – Patient treatment with NK cell products

Tschan-Plessl A. et al. (2020) Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma. *Cytotherapy*. Online ahead of print.

Cooley S. et al (2019) First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. *Blood Adv.* 3(13): 1970–1980.

Nguyen R. et al (2019) A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. *J Immunother. Cancer.* 7:81.

Vela, M. et al. (2018) Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. *Cancer Lett.* 422: 107–117.

Fehniger, T. et al. (2018) A Phase 1 Trial of CNDO-109–Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. *Biol. Blood Marrow Transplant.* 24: 1581–1589.

Adotevi, O. et al. (2018) In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial. *Oncoimmunology* 7: e1424673.

Björklund, A. et al. (2018) Complete Remission with Reduction of High-risk Clones following Haploidentical NK Cell Therapy against MDS and AML. *Clin. Cancer Res.* 24: 1834–1844.

Federico, S. M. et al. (2017) A pilot trial of humanized anti-GD2 monoclonal antibody (hu14. 18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma. *Clin. Cancer Res.* 23: 6441–6449.

Ciurea, S. O. et al. (2017) Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation. *Blood* 130: 1857–1868.

Talleur, A. C. et al. (2017) Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells. *Biol. Blood Marrow Transplant.* 23: 1910–1917.

Jaiswal, S. R. et al. (2017) CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: a pilot study. *Cytotherapy* 19: 531–542.

Romee, R. et al. (2016) Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. *Sci. Transl. Med.* 8: 357ra123–357ra123.

- Lee, D. A. *et al.* (2016) Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial. *Biol. Blood Marrow Transplant.* 22: 1290–1298.
- Shaffer, B. C. *et al.* (2016) Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation. *Biol. Blood Marrow Transplant.* 22: 705–709.
- Curti, A. *et al.* (2016) Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients. *Clin. Cancer Res.* 22: 1914–1921.
- Kottaridis, P. D. *et al.* (2015) Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: a phase I trial. *PloS one* 10: e0123416.
- Pérez-Martínez, A. *et al.* (2015) A phase I/II trial of interleukin-15-stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. *Cytotherapy* 17: 1594–1603.
- Rubnitz, J. E. *et al.* (2015) Natural killer cell therapy in children with relapsed leukemia. *Pediatr. Blood Cancer* 62: 1468–1472.
- Shah, N. N. *et al.* (2015) Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. *Blood* 125: 784–792.
- Killig, M. *et al.* (2014) Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation. *Eur. J. Immunol.* 44: 2822–2834.
- Szmania, S. *et al.* (2015) Ex vivo expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. *J. Immunother.* 38: 24–36.
- Bachanova, V. *et al.* (2014) Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. *Blood* 123: 3855–3863.
- Choi, I. *et al.* (2014) Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. *Biol. Blood Marrow Transplant.* 20: 696–704.
- Stern, M. *et al.* (2013) Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. *Bone Marrow Transplant.* 48: 433–438.
- Klingemann, H. *et al.* (2013) Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. *Transfusion* 53: 412–418.
- Parkhurst, M. R. *et al.* (2011) Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. *Clin. Cancer Res.* 17: 6287–6297.
- Curti, A. *et al.* (2011) Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. *Blood* 118: 3273–3279.
- Brehm, C. *et al.* (2011) IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. *PloS one* 6: e27351.
- Geller, M. A. *et al.* (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. *Cytotherapy*, 13: 98–107.
- Iliopoulou, E. G. *et al.* (2010) A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. *Cancer Immunol. Immunother.* 59: 1781–1789.
- Bachanova, V. *et al.* (2010) Allogeneic natural killer cells for refractory lymphoma. *Cancer Immunol. Immunother.* 59: 1739–1744.
- Huenecke, S. *et al.* (2010) IL-2– driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16– Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion. *J. Immunother.* 33: 200–210.
- Rizzieri, D. A. *et al.* (2010) Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. *Biol. Blood Marrow Transplant.* 16: 1107–1114.
- Rubnitz, J. E. *et al.* (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. *J. Clin. Oncol.* 28: 955–999.
- Passweg, J. R. *et al.* (2006) Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. *Best Pract. Res. Clin. Haematol.* 19: 811–824.
- Miller, J. S. *et al.* (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. *Blood* 105: 3051–3057.

Passweg, J. R. *et al.* (2005) Use of natural killer cells in hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 35: 637–643.

Passweg, J. R. *et al.* (2004) Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. *Leukemia* 18: 1835–1838.

2. Technical performance and NK cell functionality data and pre-clinical data

Panch A. R. (2019) Robust selections of various hematopoietic cell fractions on the CliniMACS Plus instrument. *Clicic Hemat Int* 1(3) 161-167

Oberschmidt, O. *et al.* (2019) Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering. *Hum. Gene Ther. Methods* 30: 102–120.

Williams, S. M. *et al.* (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. *Transfusion* 58: 1458–1467.

Klöß, S. *et al.* (2017) Optimization of human NK cell manufacturing: Fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells. *Hum. Gene Ther.* 28: 897–913.

Tsang, K. S. *et al.* (2017) Haploidentical natural killer cell therapy: Analysis of 205 clinimacs procedures of CD3 depletion followed by CD56 selection. *Cytotherapy* 19: S47–S48.

Van Ostaïjen-Ten Dam, M. M. *et al.* (2016) Preparation of cytokine-activated NK cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential. *J. Immunother.* 39: 90–100.

Torelli, G. F. *et al.* (2015) A good manufacturing practice method to ex vivo expand natural killer cells for clinical use. *Blood Transfus.* 13: 464–471.

Vasu, S. *et al.* (2015) A novel method to expand large numbers of CD56+ natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation. *Cytotherapy* 17: 1582–1593.

Granzin, M. *et al.* (2015) Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. *Cytotherapy* 17: 621–632.

Peragine, N. *et al.* (2015) Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients. *Cancer Immunol. Immunother.* 64: 201–211.

Brehm, C. *et al.* (2014) Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy. *Cancer Immunol. Immunother.* 63: 821–833.

Shah, N. *et al.* (2013) Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. *PLoS one* 8: e76781.

Koepsell, S. A. *et al.* (2013) Successful “in-flight” activation of natural killer cells during long-distance shipping. *Transfusion* 53: 398–403.

Lapteva, N. *et al.* (2012) Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. *Cytotherapy* 14: 1131–1143.

Siegler, U. *et al.* (2010) Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. *Cytotherapy* 12: 750–763.

Katodritou, E. *et al.* (2011) Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells. *Am. J. Hematol.* 86: 967–973.

Spanholtz, J. *et al.* (2011) Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. *PloS one* 6: e20740.

Lundqvist, A. *et al.* (2011) Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells. *J. Cancer*: 383–385.

Fujisaki, H. *et al.* (2009) Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. *Cancer Res.* 69: 4010–4017.

Berg, M. *et al.* (2009) Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. *Cytotherapy*, 11: 341–355.

Meyer-Monard, S. *et al.* (2009) Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation. *Transfusion* 49: 362–371.

McKenna Jr, D. H. *et al.* (2007) Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. *Transfusion* 47: 520–528.

Koehl, U. *et al.* (2005) Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. *Klin. Padiatr.* 217: 345–350.

Leung, W. *et al.* (2005) Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method. *Cancer Immunol. Immunother.* 54: 389–394.

Iyengar, R. *et al.* (2003) Purification of human natural killer cells using a clinical-scale immunomagnetic method. *Cytotherapy* 5: 479–484.

Lang, P. *et al.* (2002) Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children. *Bone Marrow Transplant.* 29: 497–502.

3. Reviews

Van Elssen C. H. M. J. and Ciurea S. O. (2020) NK cell alloreactivity on acute myeloid leukemia in the post-transplant cyclophosphamide era. *Am J Hematol.*

Myers, J. A. and Miller J. S. (2020) Exploring the NK cell platform for cancer immunotherapy. *Nat. Rev. Clin. Oncol.*

Hodgins, J. J. *et al.* (2019) Killers 2.0: NK cell therapies at the forefront of cancer control. *J Clin Invest.* 129(9): 3499–3510.

Suen W. C. (2018) Natural killer cell-based cancer immunotherapy: A review on 10 years completed clinical trials. *Cancer Invest.* 36(8): 431–457.

Daher, M. and Rezvani, K. (2018) Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. *Curr. Opin. Immunol.* 51: 146–153.

Granzin, M. *et al.* (2017) Shaping of natural killer cell antitumor activity by *ex vivo* cultivation. *Front. Immunol.* 8: 458.

Handgretinger, R. *et al.* (2016) Exploitation of natural killer cells for the treatment of acute leukemia. *Blood* 127: 3341–3349.

Li, Y. *et al.* (2015) NK cell-based cancer immunotherapy: from basic biology to clinical application. *Sci. China Life Sci.* 58: 1233–1245.

Davies, J. O. *et al.* (2014) Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. *Cytotherapy* 16: 1453–1466.

Bachanova, V. and Miller, J. S. (2014) NK cells in therapy of cancer. *Crit. Rev. Oncog.* 19: 133–141.

Lapteva, N. *et al.* (2014) Clinical grade purification and expansion of natural killer cells. *Crit. Rev. Oncog.* 19: 121–132.

Leung, W. (2014) Infusions of allogeneic natural killer cells as cancer therapy. *Clin. Cancer Res.* 20: 3390–3400.

Klingemann, H. G. (2013) Cellular therapy of cancer with natural killer cells—where do we stand?. *Cytotherapy* 15: 1185–1194.

Koepsell, S. A. *et al.* (2013) Natural killer cells: a review of manufacturing and clinical utility. *Transfusion* 53: 404–410.

Miller, J. S. (2013) Therapeutic applications: natural killer cells in the clinic. *Am. Soc. Hematol. Educ. Program.* 2013: 247–253.

Cheng, M. *et al.* (2013) NK cell-based immunotherapy for malignant diseases. *Cell. Mol. Immunol.* 10: 230–252.

Farhan, S. *et al.* (2012) NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. *Immunotherapy* 4: 305–313.

McKenna, D. H. *et al.* (2012) Clinical production and therapeutic applications of alloreactive natural killer cells. *Immunogenetics.* Totowa, Humana Press.

Leung, W. (2011) Use of NK cell activity in cure by transplant. *Br. J. Haematol.* 155: 14–29.

Verneris, M. R. and Grupp, S. A. (2010) Natural killer cell consolidation for acute myelogenous leukemia: a cell therapy ready for prime time?. *J. Clin. Oncol.* 28: 909–10.

Cho, D. and Campana, D. (2009) Expansion and activation of natural killer cells for cancer immunotherapy. *Korean J. Lab. Med.* 29: 89–96.

Fuchs, E. J. *et al.* (2010) HLA-haploidentical stem cell transplantation for hematologic malignancies. *Biol. Blood Marrow Transplant.* 16: S57–S63.

Miltenyi Biotec provides products and services worldwide.
Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

Changes are periodically made to the information herein; these changes will be incorporated in new editions of the publication. Miltenyi Biotec may make improvements and/or changes in the product(s) and/or the process(es) described in this publication at any time without notice.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS® GMP Products are for research use and *ex vivo* cell culture processing only, and are not intended for human *in vivo* applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.

In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC (“human tissues and cells”), or the Directive 2002/98/EC (“human blood and blood components”) – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. All other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use.

CliniMACS, CliniMACS Prodigy, MACS, and the MACS logo are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in various countries worldwide. Copyright © 2019 Miltenyi Biotec B.V. & Co KG and/or its affiliates. All rights reserved.
